CATX Perspective Therapeutics Inc

$CATX "Fast Track designation for FAP-positive solitary fibrous tumors is an important step in advancing the broader PSV359 program and our strategy of engineering targeted radiopharmaceutical therapy based on the alpha-generating isotope 212Pb to optimize the therapeutic window in oncology," said Thijs Spoor, Perspective's Chief Executive Officer. "We look forward to working with the FDA and the medical community to define an efficient development path for PSV359 in this rare and serious disease."

$CATX remember the days when a gov fast track designation was like rocket fuel for clinical bios? An indication that the science is solid and the product is performing, hence a path to profitable revenue generating company and a major derisking of the stock…now all we get is a sizzle…this news should at a minimum take it back to last funding round price $3.79.

$CATX the recent news gets more eyes on this. Data due out in 2 weeks with 22 million short. This could get very interesting.

$CATX Just to close a thought…The heavy CATX selling over the past two weeks appears largely attributable to technical market forces rather than company fundamentals. CATX’s removal from the index tracked by XBI, which previously held approximately 4 million shares, likely triggered substantial selling by XBI and potentially other index-linked funds, amplified by arbitrage and momentum trading. The absence of a new Lantheus 13D filing further reduces the likelihood that Lantheus was responsible for the continued pressure. Taken together, the evidence strongly supports index-related selling and broader biotech weakness as major contributors, rather than concerns about the upcoming ESMO results.

$CATX another announcement and they will present now on 4 different conferences with the results from Pb212 VMT 😳👍🏻🎇

$CATX pretty sure no one would schedule multiple conferences to present bad results…that being said, it would not be surprising to see this drop…maybe it’s all noise, but man it’s infuriating.

$CATX about 3 weeks for data release. Short interest is over 22 million. If they had sny concern, they should start covering as early as this upcoming week.

$CATX looks like VMT01 is back in play…after initial mediocre readouts, looks like they hav found something worthy to present…now you can get 3 assets (1 on verge of Phase 3), production facilities, $200M cash…all for under $300M…seems like a steal

$CATX Most have been here for years, Myself included. Its time 4 the CO 2 step up and give loyal longs a Dividend in shares. Let the shorts pay 4 it. Another stock held down by Kenny Griffin. Citadel controls around 60% of all trades. Cant waite 4 the creep 2 go 2 jail. Rant over. Do your dd and see how many companies are suing him.

12 U.S. trading days until the $CATX ESMO abstract releases on Monday, October 19—the first time we should see the updated efficacy/safety numbers. Sitting at 43% ORR so far. $PYXS $IOVA $SMMT

$CATX BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target Benzinga BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (CATX.NaE) with a Buy and maintains $14 price target.

$CATX buyout could come at anytime especially with manufacturing nation wide in place with excess capacity STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀🥂🥂🥂

$CATX Great data ensues. Otherwise wouldn’t have been 11 million covering. Those shorts must have had 1-on-1’s at Morgan Stanley and Oppenheimer last week. Writing on wall $237 million cash, great data and $109 million in world class manufacturing facilities with a ton of un monetized capacity. Plus lots of outlicensing inbound calls.

$CATX don't think the data bad if CATX attend on 3 different conferences in the next few weeks...

$CATX Yield environment is a lead blanket on all bio but especially clinical stage bios. If you believe in the science, patience is necessary. GLTA

$CATX Whatever is going on it doesnt matter. Oct 19 and 23, will establish the direction of our investment. Perspective will present updated VMT-α-NET data covering Cohorts 1–3, including safety and efficacy results in advanced SSTR2+ neuroendocrine tumors. The rapid oral presentation is scheduled for 4:25–4:30 p.m. Madrid time, which is 10:25–10:30 a.m. Eastern / 7:25–7:30 a.m. Pacific. Importantly, ESMO is expected to release the abstract details on October 19, so we may get meaningful data four days before the actual presentation.

$CATX omg just blow pass 3 already and stay there. This is like watching “to be continued” episodes where nothing is happening

$CATX we are at 1.6 million so far. Lets see what the last 1/2 hour gets us. Insay over 2.5 million and a ckose over 3

$CATX Somebody knows something otherwise there wouldn’t have been 7 million share buying at close on Friday

$CATX it’s the entire BIO sector.. CATX just once again always caught in the crossfire especially being 85% institutional ownership all their buy/sell is automated with risk on/off algorithms that don’t take into account catalysts… most the shares are locked up so this things moves fast in either direction Basically just bad timing with a lot of things… but nothing has changed with the fundamentals and upcoming catalysts. At this point already beaten down to the bottom nothing really more to lose basically already priced in as failure lol even tho we know thats not true … OCT 19 should be fun and it’s prolly only thing between now and then that will move this…all its peers that got bought out went to bottom right before buyout $RYZB $18 to $62 overnight $FUSN $2 to $21 🤷‍♂️